Active Pharmaceutical Ingredient (API) Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Active Pharmaceutical Ingredient (API) Market By Type of Synthesis (Biotechnological. Synthetic, Semi-Synthetic), By Application Area (Cardiovascular system, Oncology, CNS & Neurological system, Orthopaedic, Endocrinology, Pulmonology, Gastrointestinal system, Nephrology system, Ophthalmology, Others) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

The global active pharmaceutical ingredients (API) market size is projected to reach USD 251.3 billion by 2028 from USD 191.3 billion in 2021, at a CAGR of 6.1% during the forecast period. Factors such as increased drug R&D, the rising incidence of chronic diseases, the growing importance of generics, and the rising consumption of biopharmaceuticals are all driving market expansion. Unfavorable medicine price control rules in several countries, as well as high production costs, are projected to limit the market’s expansion. Government regulations that encourage API development, as well as changes in geopolitical situations, are propelling the market forward. The API market is facing significant changes as a result of COVID-19’s supply chain disruption. Due to geopolitical circumstances and a desire to lessen reliance on China for API products, countries such as India are being favoured over China for API export. Active pharmaceutical ingredient (API) is a part of the drug that produces a pharmacological effect. Some drugs such as combination therapy have multiple active pharmaceutical ingredients (API) to treat different symptoms in different ways. API’s provide health benefits and play a vital role in prevention, treatment and diagnosis. Active Pharmaceutical ingredients may synthesize by a chemical process, biotechnological process, and various other processes. Active pharmaceutical ingredients used for making the wide range of drugs that used to treat chronic diseases such as cancer, metabolic disorders, cardiovascular disorders, and neurological disorders, and others. Some market players manufacture their own API and others buy from other API manufacturing companies to make drug formulations. Active pharmaceutical ingredient (API) market is driven by various factors such as the increase in the incidence of chronic diseases, and penetration of healthcare systems in underdeveloped countries increased the consumption of drugs are expected to fuel the growth of API market. Furthermore, a surge in healthcare spending, development of healthcare infrastructure around the world enables boost the growth of active pharmaceutical ingredients market. However, unfavourable drug pricing policies in some countries and stringent regulatory requirements are hampering the Active Pharmaceutical Ingredient (API) Market.

Key Developments:

In June 2017, Bristol-Myers Squibb Company signed a definitive purchase agreement to divest its small-molecule active pharmaceutical ingredient (API) production facility in Ireland, to South Korean firm SK BIOTEK CO. LTD.

In November 2014, US-based AbbVie has acquired a small molecule active pharmaceutical ingredient (API) manufacturing site in Tuas Biomedical Park, Singapore, to expand global operations of small molecule and biologics manufacturing.

Active Pharmaceutical Ingredient (API) Market

MARKET SUMMARY
-
6.1%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 6.1%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Active Pharmaceutical Ingredient (API) Market

  • The report on global active pharmaceutical ingredient (API) market gives historical, current and future market sizes (US$ Bn) based on type of synthesis, application area and geographical regions.
  • Active Pharmaceutical Ingredient (API) Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Market Key Players
  • Pfizer
  • Sanofi
  • Lonza Group
  • Novartis
  • GlaxoSmithKline
  • Catalent
Growth

Active Pharmaceutical Ingredient (API) Market

Active Pharmaceutical Ingredient Market is witnessing robust growth rate over the forecast period. Globally API market is highly fragmented with many players. Market players are banking on mergers and acquisitions to expand their manufacturing capabilities, geographical expansions and to increase the market share. In September 2015, Sun Pharmaceuticals acquired GlaxoSmithKline’s (GSK’s) opiates business in Australia, to strengthen its active pharmaceutical ingredients (API) and analgesic drug segments. In July 2014, Hospira acquired API manufacturing facility and an associated R&D facility from Orchid Chemicals & Pharmaceuticals, an Indian pharmaceuticals company. This acquisition enables Hospira to vertically integrate into the beta-lactam antibiotic APIs. Furthermore, contract API manufacturing is growing at a significant rate owing to the low cost of manufacturing. New treatments for various diseases are expected to spur the demand for active pharmaceutical ingredients (API) across the globe.


North-America Got Significant Share

Active Pharmaceutical Ingredient (API) Market

Geographically API market segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America accounts major pie in API market over the forecast period. In addition, a rise in biotechnological advances led to rising demand for the active pharmaceutical ingredients in North America region. Asia-Pacific is expected to record the fastest CAGR owing to many manufacturers and favourable government policies in the region. Europe API market is expected to grow at a significant rate during the forecast period owing to manufacturers prioritizing high-quality standards, advanced manufacturing installations, and high purity of intermediates. In Europe, Russia active pharmaceutical market is projected to grow with significant CAGR owing to recent entry of many multinational companies and change in government policies are encouraging manufacturers to enter into the market.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share and forecast from 2022-2028
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

 

Active Pharmaceutical Ingredient (API) Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The CAGR of the active pharmaceutical ingredient market is 6.1% over the forecast period (2022 – 2028)

Pfizer, Sanofi, Lonza Group, Novartis, GlaxoSmithKline, Catalent

North America is the fastest-growing region for the active pharmaceutical ingredient market


Report

Table Of Content


Report

Company Profile

  • Pfizer, Inc. (U.S.),
  • Sanofi (France),
  • Lonza Group (Switzerland),
  • Boehringer Ingelheim (Germany),
  • Novartis AG (Switzerland),
  • GlaxoSmithKline plc (U.K.),
  • Bristol-Myers Squibb (U.S.),
  • Zhejiang Hisun Pharmaceutical Co., Ltd. (China),
  • Aenova Group GmbH (Germany),
  • Catalent, Inc. (U.S.),
  • Teva Pharmaceutical Industries Ltd., (Israel)
  • Aurobindo Pharma Limited (India),
  • Eli Lilly and Company (U.S.),
  • AbbVie Inc. (U.S.).,
  • Merck & Co., Inc. (U.S.) .

Description

The global active pharmaceutical ingredients (API) market size is projected to reach USD 251.3 billion by 2028 from USD 191.3 billion in 2021, at a CAGR of 6.1% during the forecast period. Factors such as increased drug R&D, the rising incidence of chronic diseases, the growing importance of generics, and the rising consumption of biopharmaceuticals are all driving market expansion. Unfavorable medicine price control rules in several countries, as well as high production costs, are projected to limit the market’s expansion. Government regulations that encourage API development, as well as changes in geopolitical situations, are propelling the market forward. The API market is facing significant changes as a result of COVID-19’s supply chain disruption. Due to geopolitical circumstances and a desire to lessen reliance on China for API products, countries such as India are being favoured over China for API export. Active pharmaceutical ingredient (API) is a part of the drug that produces a pharmacological effect. Some drugs such as combination therapy have multiple active pharmaceutical ingredients (API) to treat different symptoms in different ways. API’s provide health benefits and play a vital role in prevention, treatment and diagnosis. Active Pharmaceutical ingredients may synthesize by a chemical process, biotechnological process, and various other processes. Active pharmaceutical ingredients used for making the wide range of drugs that used to treat chronic diseases such as cancer, metabolic disorders, cardiovascular disorders, and neurological disorders, and others. Some market players manufacture their own API and others buy from other API manufacturing companies to make drug formulations. Active pharmaceutical ingredient (API) market is driven by various factors such as the increase in the incidence of chronic diseases, and penetration of healthcare systems in underdeveloped countries increased the consumption of drugs are expected to fuel the growth of API market. Furthermore, a surge in healthcare spending, development of healthcare infrastructure around the world enables boost the growth of active pharmaceutical ingredients market. However, unfavourable drug pricing policies in some countries and stringent regulatory requirements are hampering the Active Pharmaceutical Ingredient (API) Market.

Key Developments:

In June 2017, Bristol-Myers Squibb Company signed a definitive purchase agreement to divest its small-molecule active pharmaceutical ingredient (API) production facility in Ireland, to South Korean firm SK BIOTEK CO. LTD.

In November 2014, US-based AbbVie has acquired a small molecule active pharmaceutical ingredient (API) manufacturing site in Tuas Biomedical Park, Singapore, to expand global operations of small molecule and biologics manufacturing.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX